

Immunologia clinica

DANIELA CILLONI

Nata a Borgomanero (NO) il 26/01/1970

1995 Laurea in Medicina e Chirurgia presso Università degli Studi di Torino con voti 110/100 e lode

2000 Specializzazione in Medicina Interna presso Università degli Studi di Torino

2004 Dottorato di Ricerca in Farmacologia e Terapie Sperimentali e Cliniche -Università degli Studi di Torino

Stage formativi: 1996-1998: laboratorio di terapie cellulari-Università di Parma-Prof. C.Carlo-Stella

Carriera Universitaria: dal 28/12/2004 Ricercatore di Medicina Interna presso la facoltà di Medicina e Chirurgia dell'Università di Torino

Attività didattica svolta nel triennio 2005-2007

Docente titolare presso l'Università degli studi di Torino dei seguenti corsi :

- Immunologia Clinica – (corso integrato di patologia sistematica IV) Corso di Laurea di Medicina e Chirurgia
- Diagnostiche Biotecnologiche in Medicina Interna – Corso di Laurea Specialistica in Biotecnologie Molecolari
- Fisiopatologia Molecolare -Corso di Laurea Specialistica in Biotecnologie Mediche
- Metodiche Biotecnologiche avanzate- Corso di Laurea in Biotecnologie Veterinarie
- Docente di Medicina Interna presso la seconda scuola di Specializzazione di Medicina Interna

Attività scientifica

Autore di 74 pubblicazioni su riviste internazionali e di oltre 300 abstracts pubblicati su riviste internazionali e 5 capitoli di testi su argomenti di ematologia e oncoematologia molecolare.

Grants nel triennio 2005-2007

Titolare di grants dall'Università di Torino negli anni: 2005, 2006, 2007,2008

Grants dalla regione Piemonte negli anni 2006, 2007, 2008.

Responsabile scientifico di assegno di ricerca e borse di studio erogate dall'università di Torino nell'anno 2007

Attività editoriale: Revisore di riviste di ematologia e medicina molecolare quali Leukemia, Haematologica, Br J Haematol, Leukemia and Lymphoma, BMTransplantation

Lecture Invitate nell'ultimo triennio: oltre 50 lecture invitate a congressi e corsi nazionali, incluse: società italiana di ematologia (SIE) e società italiana di ematologia sperimentale (SIES) sui seguenti temi: leucemia mieloide cronica e malattie mieloproliferative croniche, sindromi mielodisplastiche e leucemia mieloide acuta.

Tra le principali lecture invitate a congressi internazionali:

Amsterdam 2006, European Haematology Association (EHA)

Kyoto 2006: International congress on WT1

Mandelieu 2007: chronic myeloid leukaemia-prospects for 21st century

Stoccolma 2007: EI CML congress
Berlin 2007: International congress on WT1
Budapest 2007: Next step in the evolution of targeted therapies in CML
Heidelberg 2008: European leukemia net: WT1 as a marker for MRD
Tokushima, Japan 2008 : WT1: the state of art in Europe
Osaka University, Japan 2008: WT1 as a marker of leukaemia
Torino 2008: Animal Model in CML. Ph+ Leukemias in 2008 and beyond
Boston 2008: ESH conference – CML Biological basis and therapy: Drosophila model to study Bcr-Abl pathway
Atene 2008: Iron overload in myelodysplastic syndromes

Attività clinica-sperimentale

Responsabile degli studi clinici e molecolari sulle mielodisplasie e malattie mieloproliferative Ph negative nell'ambito di gruppi di studio nazionali quali il GIMEMA working party per lo studio della leucemia mieloide cronica e sindromi ipereosinofile, GIMEMA working party per lo studio delle Trombocitemie Essenziali e gruppo Piemontese per lo Studio delle Sindromi Mielodisplastiche. E' inoltre responsabile di diversi protocolli sperimentali nazionali e internazionali per il trattamento delle leucemie acute, leucemie mieloidi croniche e sindromi mielodisplastiche:

Risultati d'apprendimento previsti

Conoscenza dei percorsi diagnostico-terapeutici più comuni nel settore dell'immunologia clinica, concetti di base sulle possibilità di diagnosi, profilassi e terapia.

Testi di riferimento

Rugarli – Medicina Interna
Harrison – Principle of Internal Medicine

Modalità di erogazione

Il corso consiste in lezioni formali e attività didattica interattiva (esercitazioni a piccoli gruppi in ambulatori e corsia).

Metodo di valutazione

L'esame consiste in una prova orale sugli argomenti svolti a lezione.

Orari di ricevimento

Dopo le lezioni o previo appuntamento.

Publicazioni ultimi 5 anni (2004-2008)

1: Breccia M, Cilloni D, Cannella L, Stefanizzi C, Tafuri A, Fama A, Santopietro M, Saglio G, Alimena G.

Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.

Cancer Chemother Pharmacol. 2008 Nov 7. [Epub ahead of print]

PMID: 18989670 [PubMed - as supplied by publisher]

2: Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, Yeh RF, Wiemels JL, Ottaviani E, Erben P, Hochhaus A, Baccarani M, Grimwade D, Preudhomme C, Apperley J, Martinelli G, Saglio G, Cross NC, Reiter A.

The molecular anatomy of the FIP1L1-PDGFR α fusion gene.

Leukemia. 2008 Nov 6. [Epub ahead of print]

PMID: 18987651 [PubMed - as supplied by publisher]

3: Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, Soverini S, Saglio G, Pane F, Baruzzi A, Vignetti M, Berton G, Vitale A, Chiaretti S, Mischen M, Foà R, Baccarani M, Martinelli G.

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method.

Haematologica. 2008 Oct 6. [Epub ahead of print]

PMID: 18838475 [PubMed - as supplied by publisher]

4: Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G.

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis.

Acta Haematol. 2008 Oct 1;120(2):70-74. [Epub ahead of print]

PMID: 18827475 [PubMed - as supplied by publisher]

5: Nicoli P, Defilippi I, Carturan S, Roetto A, Messa F, Arruga F, Messa E, Rotolo A, Iacobucci I, Bracco E, Saglio G, Cilloni D.

Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies.

Acta Haematol. 2008;120(1):47-50. Epub 2008 Sep 30. No abstract available.

PMID: 18824841 [PubMed - indexed for MEDLINE]

6: Candoni A, Tiribelli M, Toffoletti E, Cilloni D, Chiarvesio A, Michelutti A, Simeone E, Pipan C, Saglio G, Fanin R.

QUANTITATIVE ASSESSMENT OF WT1 GENE EXPRESSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IS A USEFUL TOOL FOR MONITORING MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA.

Eur J Haematol. 2008 Sep 17. [Epub ahead of print]

PMID: 18801058 [PubMed - as supplied by publisher]

7: Volpe G, Panuzzo C, Ulisciani S, Cilloni D.

Imatinib resistance in CML.

Cancer Lett. 2008 Jul 22. [Epub ahead of print]

PMID: 18653275 [PubMed - as supplied by publisher]

8: Nicoli P, Bosa M, Rotolo A, Cilloni D, Saglio G.

Herpetic leg paralysis and abdominal ileus in a patient with idiopathic myelofibrosis.

Intern Emerg Med. 2008 Jul 16. [Epub ahead of print] No abstract available.
PMID: 18629653 [PubMed - as supplied by publisher]

9: Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, Soverini S, Amabile M, Poerio A, Saglio G, Pane F, Berton G, Baruzzi A, Vitale A, Chiaretti S, Perini G, Foà R, Baccarani M, Martinelli G.

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.

Blood. 2008 Nov 1;112(9):3847-55. Epub 2008 Jul 23.

PMID: 18650450 [PubMed - indexed for MEDLINE]

10: Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M, Carturan S, Catalano R, Bracco E, Messa E, Nicoli P, Diverio D, Sanz MA, Martinelli G, Lo-Coco F, Saglio G.

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.

Haematologica. 2008 Jun;93(6):921-4. Epub 2008 Apr 28.

PMID: 18443273 [PubMed - indexed for MEDLINE]

11: Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, Pelicci PG, Mecucci C, Falini B, Saglio G; Acute Leukemia Working Party of the GIMEMA group.

Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.

Haematologica. 2008 Jul;93(7):1017-24. Epub 2008 May 27.

PMID: 18508799 [PubMed - indexed for MEDLINE]

12: Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S, Catalano R, Pautasso M, Panuzzo C, Nicoli P, Messa E, Morotti A, Iacobucci I, Martinelli G, Bracco E, Saglio G.

Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.

Leukemia. 2008 Jun;22(6):1234-40. Epub 2008 Apr 10.

PMID: 18401421 [PubMed - indexed for MEDLINE]

13: Saglio G, Ulisciani S, Bosa M, Cilloni D, Rege-Cambrin G.

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

Leuk Lymphoma. 2008 Apr;49(4):625-8. Review.

PMID: 18398722 [PubMed - indexed for MEDLINE]

14: Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M; GIMEMA Working Party on CML.

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

J Clin Oncol. 2008 Jan 1;26(1):106-11.

PMID: 18165644 [PubMed - indexed for MEDLINE]

15: Burgstaller S, Kreil S, Waghorn K, Metzgeroth G, Preudhomme C, Zoi K, White H, Cilloni D, Zoi C, Brito-Babapulle F, Walz C, Reiter A, Cross NC.

The severity of FIP1L1-PDGFR α -positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.

Leukemia. 2007 Dec;21(12):2428-32. Epub 2007 Oct 4.

PMID: 17914408 [PubMed - indexed for MEDLINE]

16: Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML.

Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase.

Haematologica. 2007 Nov;92(11):1579-80.

PMID: 18024412 [PubMed - indexed for MEDLINE]

17: Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G.

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR α -positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1.

PMID: 17666373 [PubMed - indexed for MEDLINE]

18: Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G.

Nuclear factor κ B as a target for new drug development in myeloid malignancies.

Haematologica. 2007 Sep;92(9):1224-9. Epub 2007 Aug 1. Review.

PMID: 17666366 [PubMed - indexed for MEDLINE]

19: Messa E, Cilloni D, Saglio G.

A young man with persistent eosinophilia.

Intern Emerg Med. 2007 Jun;2(2):107-12. No abstract available.

PMID: 17622494 [PubMed - indexed for MEDLINE]

20: Morotti A, Cilloni D, Parvis G, Guerrasio A, Saglio G.

Thalidomide-induced partial stable remission in a case of refractory progressive B Cell Chronic Lymphoid Leukemia.

Leuk Res. 2008 Mar;32(3):506-7. Epub 2007 Jun 4. No abstract available.

PMID: 17544506 [PubMed - indexed for MEDLINE]

21: Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I, Carturan S, Messa E, Fava M, Giugliano E, Rosso V, Catalano R, Merante S, Nicoli P, Rondoni M, Ottaviani E, Soverini S, Tiribelli M, Pane F, Baccarani M, Saglio G.

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.

Leukemia. 2007 Jul;21(7):1442-50. Epub 2007 May 17.

PMID: 17508006 [PubMed - indexed for MEDLINE]

22: Morotti A, Parvis G, Cilloni D, Familiari U, Pautasso M, Bosa M, Messa F,

Arruga F, Defilippi I, Catalano R, Rosso V, Carturan S, Bracco E, Guerrasio A, Saglio G.

CD7/CD56-positive acute myeloid leukemias are characterized by constitutive phosphorylation of the NF- κ B subunit p65 at Ser536.

Leukemia. 2007 Jun;21(6):1305-6. Epub 2007 Mar 22. No abstract available.

PMID: 17377595 [PubMed - indexed for MEDLINE]

23: Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Haematologica. 2007 Mar;92(3):401-4.

PMID: 17339191 [PubMed - indexed for MEDLINE]

24: Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR α -positive chronic eosinophilic leukemia.

Blood. 2007 Jun 1;109(11):4635-40. Epub 2007 Feb 13.

PMID: 17299092 [PubMed - indexed for MEDLINE]

25: Cilloni D, Messa E, Messa F, Carturan S, Defilippi I, Arruga F, Rosso V, Catalano R, Bracco E, Nicoli P, Saglio G.

Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.

Ann N Y Acad Sci. 2006 Nov;1089:411-23. Review.

PMID: 17261784 [PubMed - indexed for MEDLINE]

26: Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G.

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.

Haematologica. 2007 Jan;92(1):101-5.

PMID: 17229641 [PubMed - indexed for MEDLINE]

27: Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M.

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.

J Clin Oncol. 2006 Nov 20;24(33):e51-2. No abstract available.

PMID: 17114651 [PubMed - indexed for MEDLINE]

28: Martinelli G, Iacobucci I, Soverini S, Cilloni D, Saglio G, Pane F, Baccarani M.

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.

Hematol Oncol. 2006 Dec;24(4):196-204. Review.

PMID: 16988930 [PubMed - indexed for MEDLINE]

29: Morotti A, Cilloni D, Pautasso M, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Taulli R, Bracco E, Rege-Cambrin G, Gottardi E, Saglio G.

NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line.

Am J Hematol. 2006 Dec;81(12):938-45.

PMID: 16960866 [PubMed - indexed for MEDLINE]

30: Rossi D, Deambrogi C, Capello D, Cerri M, Lunghi M, Parvis G, Saglio G, Gaidano G, Cilloni D.

JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.

Br J Haematol. 2006 Oct;135(2):267-8. Epub 2006 Sep 4. No abstract available.

PMID: 16956348 [PubMed - indexed for MEDLINE]

31: Spanaki A, Linardakis E, Perdikogianni C, Stiakaki E, Morotti A, Cilloni D, Kalmanti M.

Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia.

Leuk Res. 2007 Apr;31(4):570-2. Epub 2006 Jul 31.

PMID: 16876863 [PubMed - indexed for MEDLINE]

32: Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

Clin Cancer Res. 2006 May 15;12(10):3037-42.

PMID: 16707599 [PubMed - indexed for MEDLINE]

33: Cilloni D, Gottardi E, Saglio G.

WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes.

Methods Mol Med. 2006;125:199-211.

PMID: 16502587 [PubMed - indexed for MEDLINE]

34: Merante S, Chichino G, Boveri E, Gottardi E, Soverini S, Cilloni D, Martinelli G.

First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.

J Clin Oncol. 2006 Feb 1;24(4):e6-7. No abstract available. Erratum in: J Clin

Oncol. 2006 Apr 10;24(11):1784. Serena, Merante [corrected to Merante, Serena];

Guido, Chichino [Chichino, Guido]; Emanuela, Boveri [corrected to Boveri,

Emanuela]; Enrico, Gottardi [corrected to Gottardi, Enrico]; Simona, Soverini

[Soverini, Simona]; Daniela, Cilloni [corrected to Cilloni, Daniella]; Giovanni, Martinelli[corrected to Martinelli, Giovanni].
PMID: 16446324 [PubMed - indexed for MEDLINE]

35: Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Pilatrino C, Guerrasio A, Taulli R, Bracco E, Pautasso M, Baraban D, Gottardi E, Saglio G.
Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
Cancer. 2006 Mar 1;106(5):1188-96.
PMID: 16444746 [PubMed - indexed for MEDLINE]

36: Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
J Clin Oncol. 2006 Jan 20;24(3):454-9.
PMID: 16421422 [PubMed - indexed for MEDLINE]

37: Martinelli G, Iacobucci I, Rosti G, Pane F, Amabile M, Castagnetti F, Cilloni D, Soverini S, Testoni N, Specchia G, Merante S, Zaccaria A, Frassoni F, Saglio G, Baccarani M.
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Ann Oncol. 2006 Mar;17(3):495-502. Epub 2006 Jan 10.
PMID: 16403813 [PubMed - indexed for MEDLINE]

38: Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, Carturan S, Giugliano E, Pautasso M, Bracco E, Rosso V, Sen A, Martinelli G, Baccarani M, Saglio G.
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.
Leukemia. 2006 Jan;20(1):61-7.
PMID: 16270044 [PubMed - indexed for MEDLINE]

39: Saglio G, Carturan S, Grillo S, Capella S, Arruga F, Defilippi I, Rosso V, Rauco M, Marina Liberati A, Cilloni D.
WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias.
Hematology. 2005;10 Suppl 1:76-8. Review. No abstract available.
PMID: 16188642 [PubMed - indexed for MEDLINE]

40: Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program.
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.

N Engl J Med. 2005 Sep 8;353(10):977-87.
PMID: 16148283 [PubMed - indexed for MEDLINE]

41: Pilatrinò C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, Pelicci PG, Lo Coco F, Saglio G, Guerrasio A.
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Cancer. 2005 Jul 1;104(1):101-9.
PMID: 15895376 [PubMed - indexed for MEDLINE]

42: Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M.
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
J Clin Oncol. 2005 Jun 20;23(18):4100-9. Epub 2005 May 2.
PMID: 15867198 [PubMed - indexed for MEDLINE]

43: Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.
New tyrosine kinase inhibitors in chronic myeloid leukemia.
Haematologica. 2005 Apr;90(4):534-41.
PMID: 15820950 [PubMed - indexed for MEDLINE]

44: Saglio G, Cilloni D, Rancati F, Boano L.
Glivec and CML: a lucky date.
J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):246-51. Review.
PMID: 15739279 [PubMed - indexed for MEDLINE]

45: Saglio G, Morotti A, Mattioli G, Messa E, Giugliano E, Volpe G, Rege-Cambrin G, Cilloni D.
Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.
Ann N Y Acad Sci. 2004 Dec;1028:423-31. Review.
PMID: 15650267 [PubMed - indexed for MEDLINE]

46: Cilloni D, Messa F, Carturan S, Arruga F, Defilippi I, Messa E, Gottardi E, Saglio G.
Myelodysplastic syndromes.
Ann N Y Acad Sci. 2004 Dec;1028:400-8. Review.
PMID: 15650265 [PubMed - indexed for MEDLINE]

47: Malagola M, Martinelli G, Rondoni M, Paolini S, Gaitani S, Arpinati M, Piccaluga PP, Amabile M, Basi C, Ottaviani E, Candoni A, Gottardi E, Cilloni D, Bocchia M, Saglio G, Lauria F, Fanin R, Visani G, Marrè MC, Maderna M, Rancati F, Vinaccia V, Russo D, Baccarani M.
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
Blood. 2005 Jan 15;105(2):904; author reply 905. No abstract available.

PMID: 15632213 [PubMed - indexed for MEDLINE]

48: Saglio G, Cilloni D.

Abl: the prototype of oncogenic fusion proteins.
Cell Mol Life Sci. 2004 Dec;61(23):2897-911. Review.
PMID: 15583852 [PubMed - indexed for MEDLINE]

49: Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G.

Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Cancer. 2004 Sep 1;101(5):979-88.
PMID: 15329907 [PubMed - indexed for MEDLINE]

50: Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
Blood. 2004 Dec 15;104(13):4245-51. Epub 2004 Aug 19.
PMID: 15319292 [PubMed - indexed for MEDLINE]

51: Cilloni D, Saglio G.

WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.
Acta Haematol. 2004;112(1-2):79-84. Review.
PMID: 15179007 [PubMed - indexed for MEDLINE]

52: Cilloni D, Carturan S, Gottardi E, Messa F, Fava M, Defilippi I, Arruga F, Saglio G.

Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients.
Blood. 2004 Mar 15;103(6):2428; author reply 2429. No abstract available.
PMID: 14998918 [PubMed - indexed for MEDLINE]

53: Saglio G, Cilloni D.

Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatment.
Haematologica. 2004 Jan;89(1):6-9. Review. No abstract available.
PMID: 14754599 [PubMed - indexed for MEDLINE]

54: Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Cambrin GR, Bonifazi F, Soverini S, Luatti S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G, Baccarani M; Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia.

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
Blood. 2004 Mar 15;103(6):2284-90. Epub 2003 Nov 26.
PMID: 14645009 [PubMed]

